Literature DB >> 28814386

Role of anthracycline and comprehensive geriatric assessment for elderly patients with diffuse large B-cell lymphoma.

Richard J Lin1, Madhusmita Behera2, Catherine S Diefenbach3, Christopher R Flowers2.   

Abstract

Survival outcome for elderly patients with newly diagnosed diffuse large B-cell lymphoma remains suboptimal in the rituximab era. In this systematic review, we summarize available evidence relevant to the inclusion of anthracycline in upfront chemoimmunotherapy for these elderly patients and highlight the need of prospective clinical trials. With limited prospective data, we find that pretreatment comprehensive geriatric assessment accurately predicts survival and treatment-related toxicities, suggesting its potential role in guiding overall treatment decision-making.
© 2017 by The American Society of Hematology.

Entities:  

Mesh：

Substances：

Year:  2017        PMID： 28814386      PMCID： PMC5691244          DOI： 10.1182/blood-2017-05-736975

Source DB:  PubMed          Journal:  Blood        ISSN： 0006-4971            Impact factor:   22.113


  47 in total

1.  Under-representation of older adults in cancer registration trials: known problem, little progress.

Authors:  Kevin S Scher; Arti Hurria
Journal:  J Clin Oncol       Date:  2012-04-30       Impact factor: 44.544

2.  Outcomes with R-CEOP for R-CHOP-ineligible patients with diffuse large B-cell lymphoma are highly dependent on cell of origin defined by Hans criteria.

Authors:  Armin Rashidi; Eunhye Oak; Kenneth R Carson; Nina D Wagner-Johnston; Friederike Kreisel; Nancy L Bartlett
Journal:  Leuk Lymphoma       Date:  2015-10-20

3.  The proportion of activated B-cell like subtype among de novo diffuse large B-cell lymphoma increases with age.

Authors:  Sylvain Mareschal; Hélène Lanic; Philippe Ruminy; Christian Bastard; Hervé Tilly; Fabrice Jardin
Journal:  Haematologica       Date:  2011-08-22       Impact factor: 9.941

4.  Treatment patterns and comparative effectiveness in elderly diffuse large B-cell lymphoma patients: a surveillance, epidemiology, and end results-medicare analysis.

Authors:  Paul A Hamlin; Sacha Satram-Hoang; Carolina Reyes; Khang Q Hoang; Sridhar R Guduru; Sandra Skettino
Journal:  Oncologist       Date:  2014-10-23

5.  Long-term results of the R-CHOP study in the treatment of elderly patients with diffuse large B-cell lymphoma: a study by the Groupe d'Etude des Lymphomes de l'Adulte.

Authors:  P Feugier; A Van Hoof; C Sebban; P Solal-Celigny; R Bouabdallah; C Fermé; B Christian; E Lepage; H Tilly; F Morschhauser; P Gaulard; G Salles; A Bosly; C Gisselbrecht; F Reyes; B Coiffier
Journal:  J Clin Oncol       Date:  2005-05-02       Impact factor: 44.544

6.  Geriatric Assessment-Guided Care Processes for Older Adults: A Delphi Consensus of Geriatric Oncology Experts.

Authors:  Supriya Gupta Mohile; Carla Velarde; Arti Hurria; Allison Magnuson; Lisa Lowenstein; Chintan Pandya; Anita O'Donovan; Rita Gorawara-Bhat; William Dale
Journal:  J Natl Compr Canc Netw       Date:  2015-09       Impact factor: 11.908

7.  Comparative effectiveness of anthracycline-containing chemotherapy in United States veterans age 80 and older with diffuse large B-cell lymphoma.

Authors:  Kenneth R Carson; Peter Riedell; Ryan Lynch; Chadi Nabhan; Tanya M Wildes; Weijian Liu; Arun Ganti; Ryan Roop; Kristen M Sanfilippo; Katiuscia O'Brian; Jingxia Liu; Nancy L Bartlett; Amanda Cashen; Nina Wagner-Johnston; Todd A Fehniger; Graham A Colditz
Journal:  J Geriatr Oncol       Date:  2015-01-19       Impact factor: 3.599

8.  A predictive model for aggressive non-Hodgkin's lymphoma.

Authors: 
Journal:  N Engl J Med       Date:  1993-09-30       Impact factor: 91.245

9.  Two-weekly or 3-weekly CHOP chemotherapy with or without etoposide for the treatment of elderly patients with aggressive lymphomas: results of the NHL-B2 trial of the DSHNHL.

Authors:  Michael Pfreundschuh; Lorenz Trümper; Marita Kloess; Rudolf Schmits; Alfred C Feller; Christian Rübe; Christian Rudolph; Marcel Reiser; Dieter K Hossfeld; Hartmut Eimermacher; Dirk Hasenclever; Norbert Schmitz; Markus Loeffler
Journal:  Blood       Date:  2004-03-11       Impact factor: 22.113

10.  Diffuse Large B-Cell Lymphoma in the Elderly: Real World Outcomes of Immunochemotherapy in Asian Population.

Authors:  Ja Min Byun; Jeong-Ok Lee; Beodeul Kang; Ji-Won Kim; Se Hyun Kim; Jin Won Kim; Yu Jung Kim; Keun-Wook Lee; Soo-Mee Bang; Jong Seok Lee
Journal:  Clin Lymphoma Myeloma Leuk       Date:  2016-06-08
View more
  10 in total

1.  Utility of the Geriatric 8 for the Prediction of Therapy-Related Toxicity in Older Adults with Diffuse Large B-Cell Lymphoma.

Authors:  Kana Oiwa; Kei Fujita; Shin Lee; Tetsuji Morishita; Hikaru Tsukasaki; Eiju Negoro; Takanori Ueda; Takahiro Yamauchi
Journal:  Oncologist       Date:  2020-12-30

2.  Management of older Hodgkin lymphoma patients.

Authors:  Andrew M Evens; Jordan Carter; Kah Poh Loh; Kevin A David
Journal:  Hematology Am Soc Hematol Educ Program       Date:  2019-12-06

Review 3.  Remaining challenges in predicting patient outcomes for diffuse large B-cell lymphoma.

Authors:  R Andrew Harkins; Andres Chang; Sharvil P Patel; Michelle J Lee; Jordan S Goldstein; Selin Merdan; Christopher R Flowers; Jean L Koff
Journal:  Expert Rev Hematol       Date:  2019-09-12       Impact factor: 2.929

4.  Multicenter analysis of geriatric fitness and real-world outcomes in older patients with classical Hodgkin lymphoma.

Authors:  Victor M Orellana-Noia; Krista Isaac; Mary-Kate Malecek; Nancy L Bartlett; Timothy J Voorhees; Natalie S Grover; Steven R Hwang; N Nora Bennani; Rachel Hu; Brian T Hill; Eric Mou; Ranjana H Advani; Jordan Carter; Kevin A David; Hatcher J Ballard; Jakub Svoboda; Michael C Churnetski; Gabriela Magarelli; Tatyana A Feldman; Jonathon B Cohen; Andrew M Evens; Craig A Portell
Journal:  Blood Adv       Date:  2021-09-28

5.  A population-based multistate model for diffuse large B-cell lymphoma-specific mortality in older patients.

Authors:  Çağlar Çağlayan; Jordan S Goldstein; Turgay Ayer; Ashish Rai; Christopher R Flowers
Journal:  Cancer       Date:  2019-02-01       Impact factor: 6.860

6.  A simplified frailty score predicts survival and can aid treatment-intensity decisions in older patients with DLBCL.

Authors:  Kathrine T Isaksen; Maria Adele Mastroianni; Marit Rinde; Leiv Sindre Rusten; Dlawer Abdulla Barzenje; Lloyd Frode Ramslien; Marit Slaaen; Marianne Brenn Jerm; Erlend B Smeland; Siri Rostoft; Knut Liestøl; Marianne Brodtkorb; Harald Holte
Journal:  Blood Adv       Date:  2021-11-23

7.  Prephase rituximab/prednisone therapy and aging-related, proinflammatory cytokine milieu in older, vulnerable patients with newly diagnosed diffuse large B-cell lymphoma.

Authors:  Richard J Lin; Colette N Owens; Esther Drill; Augustine Iannotta; Mayan Oliveros; Dylan L Schick; Ariela Noy; John F Gerecitano; Pamela R Drullinsky; Philip C Caron; Anita Kumar; Matthew J Matasar; Craig Moskowitz; Beatriz Korc-Grodzicki; Andrew D Zelenetz; Gilles A Salles; Paul A Hamlin
Journal:  Haematologica       Date:  2022-05-01       Impact factor: 11.047

8.  A Multicenter Study of 239 Patients Aged Over 70 Years With Diffuse Large B-Cell Lymphoma in China.

Authors:  Chunli Yang; Qiaoer Li; Ke Xie; Yakun Zhang; Dania Xiang; Yunwei Han; Liqun Zou
Journal:  Front Pharmacol       Date:  2022-07-18       Impact factor: 5.988

9.  Frontline treatments in extremely elderly patients with diffuse large B-cell lymphoma: a population-based study in Taiwan, 2010-2015.

Authors:  Huai-Hsuan Huang; Bor-Sheng Ko; Ho-Min Chen; Li-Ju Chen; Chen-Yu Wang; Fei-Yuan Hsiao
Journal:  Immun Ageing       Date:  2020-06-10       Impact factor: 6.400

10.  The beneficial effect of Escalated-R-CHOP-21 for the treatment of diffuse large B-cell lymphoma in elderly male patients: A propensity-matched cohort study.

Authors:  Hai-Xia He; Yan Gao; Bing Bai; Xiao-Xiao Wang; Ji-Bin Li; Cheng Huang; Jia-Ying Mao; Li-Qin Ping; Qi-Xiang Rong; Yan-Xia He; He Huang; Qing-Qing Cai; Zhi-Ming Li; Wen-Qi Jiang; Hui-Qiang Huang
Journal:  Cancer Med       Date:  2021-09-28       Impact factor: 4.452
  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.